As the world tries to come back to normal from the COVID-19 pandemic, although some vaccines have already received Emergency Use Authorizations (EUAs), including those developed by Pfizer and Moderna, many companies and organizations continue to run clinical trials to find vaccines and therapeutics for COVID-19. GlobalData continues to gather and analyze those COVID-19 clinical trials since the beginning of the pandemic.

Overall, the number of COVID-19 clinical trials continues to increase into 2021. As of March 8, 2021, clinical trials in the US continue to greatly outnumber those in other countries. Currently, the US has 823 clinical trials, almost double that of India, which is second with 491 clinical trials. China, Iran, and Spain round out the top five, all of which have more than 200 COVID-19 clinical trials. China has had the slowest increase, which can be seen in Figure 1 below. The number of clinical trials for China slowly increased from 318 to 488 over the course of the pandemic, an almost flat line compared to the US and India.

With the number of COVID-19 clinical trials continuing to rise all over the world, analysis will continue to clarify which countries will have the most trials. While the US will continue to dominate, India expects to continue to increase their number of clinical trials, as seen with the steep increase in the graph below.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.